SOURCE-LINKED STUDY SUMMARY
Daridorexant in severe obstructive sleep apnea: effects on sleep-disordered breathing and sleep.
Full paper summarizedQuality not appraised
- What was studied
- A double-blind randomized crossover trial tested daridorexant effects on breathing and sleep in severe sleep apnea.
- Who / model studied
- 16 adults with severe obstructive sleep apnea without insomnia, studied at one center.
- Studied dose & schedule
- Oral daridorexant 50 mg or placebo each evening for 5 days per treatment period.
- What the study found
- No clinically meaningful average worsening of apnea frequency or oxygen saturation was detected. Total sleep increased by 32.5 minutes versus placebo (90% CI 6.9-58.2). Reported adverse events were mild.
- Limitations & context
- Small, short study in a selected population without insomnia. Average results do not guarantee individual respiratory safety or establish long-term safety; this was not an apnea-treatment trial.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1093/sleep/zsag145